Oriented attachment of V_NAR proteins, via site-selective modification, on PLGA-PEG nanoparticles enhances nanoconjugate performance.

ABSTRACT: Herein we report the construction of a nanoparticle-based drug delivery system which targets a key regulator in tumour angiogenesis. We exploit a Variable New Antigen Receptor (VNAR) domain, conjugated using site-specific chemistry, to direct poly lactic acid-co-glycolic acid-polyethylene glycol (PLGA-PEG) nanoparticles to delta like canonical Notch ligand 4 (DLL4). The importance of site-specific chemistry is demonstrated.

SUBMITTER: Nogueira JCF 

PROVIDER: S-EPMC6873773 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature